Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ: Androgen receptor term when you look at the the hormone estrogen receptor-negative breast cancer

Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ: Androgen receptor term when you look at the the hormone estrogen receptor-negative breast cancer

Bieche I, Parfait B, Tozlu S, Lidereau Roentgen, Vidaud Yards: Quantitation from androgen receptor gene term for the sporadic breast cancers from the real-date RT-PCR: evidence one MYC try an enthusiastic AR-managed gene. Carcinogenesis. 2001, 22 (9): 1521-1526. /carcin/22.9.1521.

Bratthauer GL, Lininger RA, Man YG, Tavassoli FA: Androgen and you will estrogen receptor mRNA position within the apocrine carcinomas. Diagn Mol Pathol. 2002, 11 (2): 113-118. 9606-200206000-00008.

Gatalica Z: Immunohistochemical data of apocrine breast lesions. Consistent more than-expression from androgen receptor with losing estrogen and you may progesterone receptors into the apocrine metaplasia and you can apocrine carcinoma from inside the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.

Are J Clin Pathol

Soreide JA, Lea OA, Varhaug JE, Skarstein A beneficial, Kvinnsland S: Androgen receptors for the operable cancer of the breast: reference to most other steroid hormone receptors, correlations in order to prognostic factors and you can predictive value for aftereffect of adjuvant tamoxifen treatment. Eur J https://datingranking.net/tr/squirt-inceleme/ Surg Oncol. 1992, 18 (2): 112-118.

Bayer-Gather IB, Smoller B: Androgen receptors: a beneficial marker to improve sensitivity for distinguishing cancer of the breast within the epidermis metastasis out-of unknown pri, thirteen (2): 119-122. /modpathol.3880021.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic craft and you can systematic implications. J Clin Oncol. 2000, 18 (5): 1135-1149.

Pang ST, Flores-Morales A great, Skoog L, Chuan YC, Nordstedt Grams, Pousette Good: Controls of matrix metalloproteinase thirteen term by androgen in prostate disease. Oncol Associate. 2004, eleven (6): 1187-1192.

Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.

Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Investigations of one’s prognostic need for androgen receptor term for the metastatic breast cancer. Virchows Arch. 2006, 449 (1): 24-30. /s00428-00six-0213-six.

Parker RL, Hunter DG, Lesack DW, Cupples JB, Give DR, Akbari Yards, Gilks CB: Comparison off interlaboratory type from the immunohistochemical dedication regarding the hormone estrogen receptor updates playing with a cancer of the breast structure microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.

Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Study of matrix metalloproteinases in addition to their inhibitors inside the breast cancer. Br J Disease. 2007, 96 (6): 903-911. /sj.bjc.6603666.

Narita D, Raica M, Suciu C, Cimpean Good, Anghel Good: Immunohistochemical term regarding androgen receptor and you can prostate-particular antigen inside the breast cancer. Folia Histochem Cytobiol. 2006, 49 (3): 165-172.

Egeblad M, Werb Z: The fresh new features into the matrix metalloproteinases into the cancer development. Nat Rev Disease. 2002, 2 (3): 161-174. /nrc745.

Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–for the fundamental phase of cancer?. Cancers Telephone. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.

Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Age, Martinez Ac: The newest matrix metalloproteinase-nine controls the new insulin-particularly development basis-brought about autocrine effect when you look at the DU-145 carcinoma structure. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..

Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M: Release of an intrusion supporter Elizabeth-cadherin fragment of the matrilysin and you may stromelysin-1. J Mobile Sci. 2001, 114 (Pt step 1): 111-118.

Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] term selects to have structure with reduced sensitivity to help you apoptosis. Neoplasia. 2001, step three (6): 459-468. /sj.neo.7900190.

CO;2-H

Stetler-Stevenson WG: Matrix metalloproteinases during the angiogenesis: a relocation target getting therapeutic intervention. J Clin Dedicate. 1999, 103 (9): 1237-1241. /JCI6870.

Cornelius La, Nehring LC, Harding Elizabeth, Bolanowski Meters, Welgus HG, Kobayashi DK, Enter RA, Shapiro SD: Matrix metalloproteinases make angiostatin: outcomes on neovascularization. J Immunol. 1998, 161 (12): 6845-6852.

Jiang Y, Goldberg ID, Shi YE: Cutting-edge roles from structure inhibitors off metalloproteinases when you look at the disease. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.